Page 316 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPTEr 20 Host Defenses at Mucosal Surfaces 297

responses are diminished in aged animals, especially those in 17. Csencsits KL, Jutila MA, Pascual DW. Nasal-associated lymphoid tissue:
56
GALTs. In older humans, pathogens that invade through mucosal phenotypic and functional evidence for the primary role of peripheral
surfaces, such as influenza virus and the bacterial pathogen node addressin in naïve lymphocyte adhesion to high endothelial venules
Streptococcus pneumoniae, cause more severe and more frequently in a mucosal site. J Immunol 1999;163:1382–9.
lethal infections. The development of effective vaccines for older 18. Wolber FM, Curtis JL, Milik AM, et al. Lymphocyte recruitment and the
kinetics of adhesion receptor expression during the pulmonary immune
adults remains a largely unmet goal. To provide effective protection response to particulate antigen. Am J Pathol 1997;151:1715–27.
against influenza and S. pneumoniae for this population, one 19. Quiding-Jarbrink M, Nordstrom I, Granstrom G, et al. Differential
should strongly consider developing a new generation of vaccines expression of tissue-specific adhesion molecules on human circulating
that could induce pathogen-specific immunity in the respiratory antibody-forming cells after systemic, enteric, and nasal immunizations.
tract. Although it has been shown that effective protection can A molecular basis for the compartmentalization of effector B cell
be provided by pathogen-specific systemic IgG without mucosal responses. J Clin Invest 1997;99:1281–6.
IgA responses, pathogen-specific sIgA responses are a necessary 20. Lambrecht BN, Iwasaki A, Kelsall BL. Mucosal dendritic cells: Origins,
component for providing a first line of effective immunity against Subsets, and Biology. In: Mestecky J, Strober W, Russell MW, et al, editors.
these respiratory pathogens at their entry site. Mucosal immunology. 4th ed. Cambridge, MA: Elsevier; 2015. p. 489–541.
21. Widhe M, Ekerfelt C, Forsberg P, et al. IgG subclasses in Lyme borreliosis:
a study of specific IgG subclass distribution in an interferon-gamma-
Please check your eBook at https://expertconsult.inkling.com/ predominated disease. Scand J Immunol 1998;47:575–81.
for self-assessment questions. See inside cover for registration 22. Moser B. CXCR5, the defining marker for follicular B helper T (TFH)
details. cells. Front Immunol 2015;6:296.
23. Tsuji M, Komatsu N, Kawamoto S, et al. Preferential generation of
REFERENCES follicular B helper T cells from Foxp3+ T cells in gut Peyer’s patches.
Science 2009;323:1488–92.
1. Kiyono H, Kunisawa J, McGhee JR, et al. The Mucosal Immune System. 24. Kato LM, Kawamoto S, Maruya M, et al. Gut TFH and IgA: key players
In: Paul WE, editor. Fundamental immunology. 5th ed. Philadelphia, PA: for regulation of bacterial communities and immune homeostasis.
Lippincott Williams & Wilkins; 2008. p. 983–1030. Immunol Cell Biol 2014;92:49–56.
2. Baker K, Blumberg RS, Kaetzel CS. Immunoglobulin transport and 25. Cerutti A, Chen K, Chorny A. Immunoglobulin responses at the mucosal
immunoglobulin receptors. In: Mestecky J, Strober W, Russell MW, et al, interface. Annu Rev Immunol 2011;29:273–93.
editors. Mucosal immunology. 4th ed. Cambridge, MA: Elsevier; 2015. 26. Fujihashi K, McGhee JR, Lue C, et al. Human appendix B cells naturally
p. 349–407. express receptors for and respond to interleukin 6 with selective IgA1 and
3. Clevers HC, Bevins CL. Paneth cells: maestros of the small intestinal IgA2 synthesis. J Clin Invest 1991;88:248–52.
crypts. Annu Rev Physiol 2013;75:289–311. 27. Fujihashi K, McGhee JR. Th1/Th2/Th3 cells for regulation of mucosal
4. Collonna M, Fuchs A, Cella M. Innate lymphoid cells in mucosal immunity, tolerance and inflammation. In: Mestecky J, Lamm ME,
homeostasis, infections, autoimmune disorders, and tumors. In: Mestecky Strober W, et al, editors. Mucosal immunology. 3rd ed. Part I, Chapter 28.
J, Strober W, Russell MW, et al, editors. Mucosal immunology. 4th ed. Cambridge, MA: Elsevier Inc.; 2005. p. 539–58.
Cambridge, MA: Elsevier; 2015. p. 1003–12. 28. Duverger A, Carre JM, Jee J, et al. Contributions of edema factor and
5. Serafini N, Di Santo JP. Effector cells of mucosal immune system: innate protective antigen to the induction of protective immunity by Bacillus
lymphoid cells. In: Mestecky J, Strober W, Russell MW, et al, editors. anthracis edema toxin as an intranasal adjuvant. J Immunol
Mucosal immunology. 4th ed. Cambridge, MA: Elsevier; 2015. p. 787–804. 2010;185:5943–52.
6. Williams IR, Owen RL. M cells: Specialized antigen sampling cells un the 29. Mancini P, Santi PA. Localization of the GM1 ganglioside in the
follicle-associated epithelium. In: Mestecky J, Strober W, Russell MW, vestibular system using cholera toxin. Hear Res 1993;64:151–65.
et al, editors. Mucosal immunology. 4th ed. Cambridge, MA: Elsevier; 30. van Ginkel FW, Jackson RJ, Yuki Y, et al. Cutting edge: the mucosal
2015. p. 211–30. adjuvant cholera toxin redirects vaccine proteins into olfactory tissues.
7. Kiyono H, Fukuyama S. NALT- versus Peyer’s-patch-mediated mucosal J Immunol 2000;165:4778–82.
immunity. Nat Rev Immunol 2004;4:699–710. 31. Yamamoto S, Kiyono H, Yamamoto M, et al. A nontoxic mutant of
8. Woof JM, Mestecky J. Mucosal immunoglobulins. In: Mestecky J, Strober cholera toxin elicits Th2-type responses for enhanced mucosal immunity.
W, Russell MW, et al, editors. Mucosal immunology. 4th ed. Cambridge, Proc Natl Acad Sci USA 1997;94:5267–72.
MA: Elsevier; 2015. p. 287–324. 32. Rappuoli R, Pizza M, Douce G, et al. Structure and mucosal adjuvanticity
9. Randall TD, Carragher DM, Rangel-Moreno J. Development of secondary of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today
lymphoid organs. Annu Rev Immunol 2008;26:627–50. 1999;20:493–500.
10. van de Pavert SA, Mebius RE. New insights into the development of 33. Lycke N, Bemark M. Mucosal adjuvants and long-term memory
lymphoid tissues. Nat Rev Immunol 2010;10:664–74. development with special focus on CTA1-DD and other ADP-ribosylating
11. Brandtzaeg P. Potential of nasopharynx-associated lymphoid tissue for toxins. Mucosal Immunol 2010;3:556–66.
vaccine responses in the airways. Am J Respir Crit Care Med 34. Fukuyama Y, Ikeda Y, Ohori J, et al. A molecular mucosal adjuvant to
2011;183:1595–604. enhance immunity against pneumococcal infection in the elderly.
12. Knop N, Knop E. Conjunctiva-associated lymphoid tissue in the human Immune Netw 2015;15:9–15.
eye. Invest Ophthalmol Vis Sci 2000;41:1270–9. 35. Le Bon A, Schiavoni G, D’Agostino G, et al. Type I interferons potently
13. Nagatake T, Fukuyama S, Kim DY, et al. Id2-, RORγt-, and LTβR- enhance humoral immunity and can promote isotype switching by
independent initiation of lymphoid organogenesis in ocular immunity. stimulating dendritic cells in vivo. Immunity 2001;14:461–70.
J Exp Med 2009;206:2351–64. 36. Perez-Giron JV, Belicha-Villanueva A, Hassan E, et al. Mucosal
14. Habtezion A, Nguyen LP, Hadeiba H, et al. Leukocyte Trafficking to the polyinosinic-polycytidylic acid improves protection elicited by replicating
Small Intestine and Colon. Gastroenterology 2016;150:340–54. influenza vaccines via enhanced dendritic cell function and T cell
15. Czerkinsky C, Holmgren J. Mucosal delivery routes for optimal immunity. J Immunol 2014;193:1324–32.
immunization: targeting immunity to the right tissues. Curr Top 37. Boyaka PN, Marinaro M, Jackson RJ, et al. IL-12 is an effective adjuvant
Microbiol Immunol 2012;354:1–18. for induction of mucosal immunity. J Immunol 1999;162:122–8.
16. Brandtzaeg P. The mucosal B cell system. In: Mestecky J, Strober W, 38. Williamson E, Westrich GM, Viney JL. Modulating dendritic cells to
Russell MW, et al, editors. Mucosal immunology. Cambridge, MA: optimize mucosal immunization protocols. J Immunol 1999;163:
Elsevier; 2015. p. 623–81. 3668–75.